http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121015:nBw155576a
   Company`s Novel Cardiac Biomarker To Become Available in Germany, France, Spain,Portugal and TurkeySAN DIEGO--(Business Wire)--Critical Diagnostics, a U.S.-based biomarker company focused on cardiovasculardiseases, today announced that it has signed agreements with four new Europeandistributors in Germany, Spain, France and Turkey. "Just recently, one of the largest hospitals in Barcelona established a protocolof using Presage ST2 Assay as part of the standard of care for managing patientswith heart failure," says James Snider, President of Critical Diagnostics. "Evermore convincing clinical data is coming in on ST2`s value in prognosis and careof heart failure patients. In these days of austerity, an assay that canactively improve patient outcomes while reducing overall health care costs is ingreat demand." AboutBestbionCritical Diagnostics has chosen Bestbion dx GmbH as its exclusive distributor inGermany. Headquartered in Cologne, Bestbion has a highly skilled team, one thathelped to launch BNP in Germany. Their existing network of contacts andknowledge of cardiac biomarkers is second to none. About INyDIAIn Spain and Portugal, Critical Diagnostics have partnered with Madrid-basedINyDIA. INyDIA have been instrumental in helping Critical Diagnostics to gain afoothold in the competitive Spanish market with the Company`s first clinicalplacement at the Hospital Germans Trias i Pujol in Barcelona. About EurobioIn France the Company`s new partner will be Eurobio AbCys. Based in Paris, this50-year old company headed up by Jean-Michel Carle and his team of seasonedprofessionals, have extensive experience of launching new biomarkers in France,including BNP and NGAL. About Savas MedikalCompleting this phase of growth is Savas Medikal, based in Istanbul, Turkey.Savas Medikal have been serving the Turkish medical diagnostics market fornearly 20 years. They are also the exclusive distributors of several well-knowncardiovascular diagnostic products. "We have carefully chosen established, quality distributors," notes RichardHughes, Vice President, Business Development Europe for Critical Diagnostics."Each has successfully launched new biomarkers in their respective markets, andbelieve, like us, that ST2 will be a critical new tool in the evolution of heartfailure patient management." About ST2ST2 has now been published in more than 50 peer-reviewed articles studying morethan 31,000 patients. These clinical studies have demonstrated that high levelsof soluble ST2 are predictive of adverse patient outcomes and death in a broadspectrum of cardiovascular disease. They have further shown that the prognosticinformation from soluble ST2 is independent and provides added information tocardiac biomarkers commonly used today, including the natriuretic peptides, BNPand NT-proBNP. About Critical Diagnostics and ST2Critical Diagnostics (
  www.criticaldiagnostics.com
 ) develops novel biomarkers tohelp physicians optimize patient care in cardiovascular diseases, whilecontaining healthcare costs. The Presage ST2 Assay has been CE Marked andcleared by the US FDA for use in risk stratification with chronic heart failurepatients. Critical Diagnostics has exclusive worldwide rights to ST2 for thediagnosis and prognosis of cardiovascular disease.  Critical DiagnosticsDennis Dalangin, VP MarketingTelephone: 877-700-1250Email: ddalangin@criticaldiagnostics.comCopyright Business Wire 2012